Sera Prognostics Inc. (NASDAQ:SERA), a company focused on maternal health diagnostics, reported its financial results for the fourth quarter and full year of 2025. The earnings release revealed a significant revenue shortfall against analyst expectations, though the company's net loss per share was slightly better than forecast. The immediate market reaction in after-hours trading was negative.
Earnings Miss on Revenue, EPS Narrowly Beats
The core financial metrics from the fourth quarter presented a mixed picture. The most glaring figure was the company's reported revenue, which fell dramatically short of the consensus estimate.
- Reported Q4 2025 Revenue: $10,000
- Analyst Estimate for Q4 2025 Revenue: $30,600
This substantial miss indicates commercial adoption of the company's flagship PreTRM® test, a blood-based biomarker test to predict preterm birth risk, is progressing slower than analysts had modeled for the period. In contrast, the bottom-line result showed a smaller-than-expected loss.
- Reported Q4 2025 Non-GAAP EPS: -$0.16
- Analyst Estimate for Q4 2025 Non-GAAP EPS: -$0.19
The narrower loss per share suggests Sera Prognostics is managing its operating expenses effectively, even as sales growth lags.
Market Reaction and Recent Performance
The initial investor response to the earnings report was unfavorable. Following the release, the stock traded down approximately 2.6% in after-market activity. This decline reflects the market's primary focus on the top-line revenue miss, which overshadowed the modest beat on the earnings per share figure.
This negative after-hours move extends a period of weakness for the stock. Over the past month, shares of Sera Prognostics have declined by roughly 22.4%, indicating broader investor concerns leading up to the earnings announcement. Performance over the past two weeks and week has been relatively flat, showing little positive momentum.
Looking Ahead: Analyst Expectations for 2026
While the press release summarized past performance, it did not provide formal financial guidance for the coming year. However, analyst estimates for 2026, which were available prior to the earnings release, project a path toward significant revenue growth, albeit alongside continued losses.
For the upcoming first quarter of 2026, the consensus estimates are:
- Estimated Q1 2026 Revenue: $132,600
- Estimated Q1 2026 EPS: -$0.18
For the full 2026 fiscal year, analysts are modeling:
- Estimated FY 2026 Revenue: $790,500
- Estimated FY 2026 EPS: -$0.71
These projections set a high bar for the company's commercial execution in the year ahead. Investors will be watching closely to see if Sera can begin to align its reported revenues with these forecasts, starting with the Q1 2026 results.
Summary of the Earnings Release
The company's press release emphasized its ongoing commercial and clinical initiatives rather than the quarterly financials. Key highlights included the continued commercialization of the PreTRM test, ongoing efforts to secure broader insurance coverage, and advancements in its clinical pipeline. Management reiterated its commitment to its mission of improving maternal and neonatal health through its biomarker technology platform. The financial results were framed within the context of these longer-term strategic investments.
For a detailed view of Sera Prognostics' historical earnings and future analyst projections, you can review the earnings history and current estimates.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.